Focal Segmental Glomerulosclerosis and Chronic Kidney Disease in Pediatric Patients

Advances in Chronic Kidney Disease

Volumn 18, Issue 5, 2011, Pages 332-338

  Kiffel, Jeremy ^a   Rahimzada, Yael ^a   Trachtman, Howard ^a  

^a Northwell Health   (United States)

Author keywords

FSGS

Indexed keywords

ADALIMUMAB; ATORVASTATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; LISINOPRIL; LOSARTAN; METHYLPREDNISOLONE; TACROLIMUS;

APOPTOSIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONSERVATIVE TREATMENT; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG PULSE THERAPY; ELECTRON MICROSCOPY; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MEDICAL HISTORY; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; CHILD; CHILD, PRESCHOOL; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; PODOCYTES; RENAL INSUFFICIENCY, CHRONIC;

EID: 80052409838     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.03.005     Document Type: Review

References (66)

1. D'Agati V. Pathological classification of focal segmental glomerulosclerosis. Semin Nephrol 2003, 23:117-134.
2. Stokes M.B., Valeri A.M., Markowitz G.S., D'Agati V.D. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int 2006, 70:1783-1792.
3. Chun M.J., Korbet S.M., Schwartz M.M., Lewis E.J. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004, 15:2169-2177.
4. Jennette J.C., Hipp C.G. C1q nephropathy; a distinct pathologic entity usually causing nephrotic syndrome. Am J Kid Dis 1985, 6:103-110.
5. Markowitz G.S., Schwimmer J.A., Stokes M.B., et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int 2003, 64:1232-1240.
6. Gipson DG, Trachtman H, Kaskel FJ, et al. Multicenter FSGS clinical trial: study design, clinical features, and quality of life of the study cohort at baseline. Kidney Int. In press.
7. Łodzi U.M., Nefropatologii Z. Focal segmental glomerulosclerosis-the disease entity or histological type of glomerular injury? [in Polish]. Pol Merkur Lekarski 2010, 28:482-485.
8. Srivastava T., Garola R.E., Whiting J.M., Alon U.S. Synaptopodin expression in idiopathic nephrotic syndrome in childhood. Kidney Int 2001, 59:118-125.
9. Giannico G., Yang H., Neilson E.G., Fogo A.B. Dystroglycan in the diagnosis of FSGS. Clin J Am Soc Nephrol 2009, 4:1747-1753.
10. Srivastava T., Garola R.E., Whiting J.M., Alon U.S. Cell-cycle regulatory proteins in podocyte cell in idiopathic nephrotic syndrome of childhood. Kidney Int 2003, 63:1374-1381.
11. Shui H.A., Huang T.H., Ka S.M., Chen P.H., Lin Y.F., Chen A. urinary proteome and potential biomarkers associated with serial pathogenesis steps of focal segmental glomerulosclerosis. Nephrol Dial Transplant 2008, 23:176-185.
12. Dijkman H.B., Weening J.J., Smeets B., et al. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal cells. Kidney Int 2006, 70:338-344.
13. Costero O., Picazo M.L., Zamora P., et al. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 2010, 25:1001-1003.
14. Markowitz G.S., Nasr S.H., Stokes M.B., D'Agati V. Treatment with IFN-α, -β, or -γ is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010, 5:607-615.
15. Dingli D., Larson D.R., Plevak M.F., Grande J.P., Kyle R.A. Focal and segmental glomerulosclerosis and plasma cell proliferative disorders. Am J Kidney Dis 2005, 46:278-282.
16. Hodgin J.B., Rasoulpour M., Markowitz G.S., D'Agati V. Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009, 4:71-76.
17. Herlitz L.C., Markowitz G.S., Farris A.B., et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010, 21:163-172.
18. Srivastava T., Simon S.D., Alon U.S. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 2009, 13:13-18.
19. Filler G., Young E., Geier P., Carpenter B., Drukker A., Feber J. Is there really an increase in nonminimal change nephrotic syndrome in children?. Am J Kid Dis 2003, 42:1107-1113.
20. Swaminathan S., Leung N., Lager D.J., et al. Changing incidence of glomerular disease in Olmstead County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006, 1:483-487.
21. Barisoni L., Schnaper H.W., Kopp J.B. Advance in the biology and genetics of the podocytopathies: implications for diagnosis and therapy. Arch Pathol Lab Med 2009, 133:201-216.
22. Wharram B.L., Goyal M., Wiggins J.E., et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005, 16:2941-2952.
23. Niranjan T., Bielesz B., Gruenwald A., et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med 2008, 14:2908.
24. Kaufman L., Potla U., Coleman S., et al. Up-regulation of the homophilic adhesion molecule Sidekick-1 in podocytes contributes to glomerulosclerosis. J Biol Chem 2010, 285:25677-25685.
25. Boute N., Gribouval O., Roselli S., et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000, 24:349-354.
26. Gigante M., Pontrelli P., Montemurno E., et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant 2009, 24:1858-1864.
27. Phillipe A., Nevo F., Esquivel E.L., et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008, 19:1871-1878.
28. Kopp J.B., Smith M.W., Nelson G.W., et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008, 40:1175-1184.
29. Genovese G., Friedman D.J., Ross M.D., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329. 841-85l.
30. Genovese G., Tonna S.J., Knob A.U., et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010, 78:698-704.
31. Caridi G., Gigante M., Ravani P., et al. Clinical features and long-term outcome of nephrotic syndrome associated with heterozygous NPHS1 and NPHS2 mutations. Clin J Am Soc Nephrol 2009, 4:1065-1072.
32. Hinkes B., Vlangos C., Heeringa S., et al. Specific podocin mutations correlate with age of onset of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008, 19:365-371.
33. Chernin G., Vega-Warner V., Schoeb D.S., et al. Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations. Clin J Am Soc Nephrol 2010, 5:1655-1662.
34. Moranne O., Watier L., Rossert J., Stengel B. Primary glomerulonephritis: an update on renal survival and determinants of progression. QJM 2008, 101:215-224.
35. Sozeri B., Mir S., Mutlubas F., et al. The long-term results of pediatric patients with primary focal and segmental glomerulosclerosis. Saudi J Kidney Dis Transpl 2010, 21:87-92.
36. Boyer O., Moulder J.K., Somers M.J. Focal and segmental glomerulosclerosis in children: a longitudinal assessment. Pediatr Nephrol 2007, 22:1159-1166.
37. Troyanov S., Wall C.A., Miller J.A., et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005, 16:1061-1068.
38. Leaf D.E., Appel G.B., Radhakridshnan J. Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney Int 2010, 78:337-342.
39. Meyrier A.Y. Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?. Kidney Int 2009, 76:487-491.
40. Faul C., Donnelly M., Merscher-Gomez S., et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008, 14:931-938.
41. Gulati A., Sinha A., Jordan S.C., et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010, 5:2207-2212.
42. McCarthy E.T., Sharma M., Sharma R., Falk R.J., Jennette J.C. Sera from patients with collapsing focal segmental glomerulosclerosis increase albumin permeability of isolated glomeruli. J Lab Clin Med 2004, 143:225-229.
43. Savin V.J., Sharma M. Plasma " factors" in recurrent nephrotic syndrome after kidney transplantation. Am J Kid Dis 2009, 54:406-409.
44. Savin V.J., McCarthy, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol 2003, 23:147-160.
45. Savin V.J., McCarthy E.T., Sharma R., Charba D., Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res 2008, 151:288-292.
46. Meyrier A., Simon P. Treatment of corticoresistant idiopathic nephrotic syndrome in the adult: minimal change disease and focal segmental glomerulosclerosis. Adv Nephrol Necker Hosp 1988, 17:127-150.
47. Braun N., Schmutzler F., Lange C., et al. Immunosuppressive treatment of focal segmental glomerulosclerosis. Cochrane Database Syst Rev 2008, 16:CD003233.
48. Mendoza S.A., Reznik V.M., Griswold W.R., et al. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr Nephrol 1990, 4:303-307.
49. Lieberman K., Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis. J Am Soc Nephrol 1996, 7:56-63.
50. Cattran D.C., Appel G.B., Hebert L.A., et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 1999, 56:2220-2226. North America nephrotic Syndrome Study Group.
51. Bhimma R., Adhikari M., Asharam K., Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 2006, 26:544-551.
52. Duncan N., Dhaygude A., Owen J., et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004, 19:3062-3067.
53. Choi M.J., Eustace J.A., Gimenez L.F., et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002, 61:1098-1114.
54. Cattran D.C., Wang M.M., Appel G., Matalon A., Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004, 62:405-411.
55. Pescovitz M.D., Book B.K., Sidner R.A. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006, 354:1961-1963.
56. Fernandez-Fresnedo G., Segarra A., Gonzalez E., et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009, 4:1317-1323.
57. Trachtman H., Vento S., Gipson D., et al. Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design. BMC Nephrol 2011, 12:8.
58. Crosson J.T. Focal segmental glomerulosclerosis and renal transplantation. Transplant Proc 2007, 39:737-743.
59. Gohn R.Y., Yango A.F., Morrissey P.E., et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005, 5:2907-2912.
60. Ruf R.G., Lichtenberger A., Karle S.M., et al. Patients with mutations in NPHS2 (podsocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004, 15:722-732.
61. Jungraithmayr T.C., Hofer K., Cochat P., et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 2011, 22:579-585.
62. Hickson L.J., Gera M., Amer H., et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009, 87:1232-1239.
63. Mitome J., Yamamoto H., Maruyama Y., et al. Successful treatment of recurrent focal segmental glomerulosclerosis combined with calcineurin inhibitor nephrotoxicity four years after kidney transplantation. Clin Transplant 2010, 24:48-53.
64. Tsagalis G, Psimenou E, Nakopoulou L, et al. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs. In press.
65. Sethna C, Benchimol C, Hotchkiss H, et al. Treatment of recurrent focal segmental glomerulosclerosis (FSGS) in pediatric kidney transplant recipients: effect of rituximab. J Transplant. In press.
66. Rodríguez-Ferrero M., Ampuero J., Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc 2009, 6:2406-2408.